Estimation and comparison of ganciclovir exposure following intravenous ganciclovir or oral valganciclovir administration and the effect of ganciclovir exposure on the efficacy and safety in pediatric patients after liver transplantation
-
- SAITO Jumpei
- National Center for Child Health and Development Department of Pharmacy
-
- ISHIHARA Satomi
- National Center for Child Health and Development Department of Pharmacy
-
- UCHIDA Hajime
- National Center for Child Health and Development Organ Transplantation Center
-
- SASAKI Kengo
- National Center for Child Health and Development Organ Transplantation Center
-
- NARUMOTO Soichi
- National Center for Child Health and Development Organ Transplantation Center
-
- SAKAMOTO Seisuke
- National Center for Child Health and Development Organ Transplantation Center
-
- FUKUDA Akinari
- National Center for Child Health and Development Organ Transplantation Center
-
- KASAHARA Mureo
- National Center for Child Health and Development Organ Transplantation Center
-
- ISHIKAWA Yoichi
- National Center for Child Health and Development Department of Pharmacy
Bibliographic Information
- Other Title
-
- 小児肝移植患者における静注ganciclovirと経口valganciclovirのAUC同等性比較と有効性・安全性に関する検討
Search this article
Abstract
<p>【Objective】Ganciclovir (GCV) and valganciclovir (VGCV) are used for the treatment and preemptive therapy of cytomegalovirus infection in pediatric liver transplantation patients. A GCV 24-hour area under the time-concentration curve (AUC0-24) of 40 – 60 μg/mL⋅hr is related to efficacy. The primary objective was to compare systemic exposures of GCV in patients administered GCV or VGCV using AUC0-24. Secondary objectives were the evaluation of causal relationships between AUC0-24 and efficacy or adverse effects.<br/> 【Study Design】Retrospective case series study.<br/> 【Methods】A limited sampling strategy was used to estimate AUC0-24. The time to a clearance of pp65 antigenemia was used as an efficacy, and incidences of renal and hematological toxicity were used as a safety.<br/> 【Results】Twenty-two pediatric liver transplantation patients were enrolled in the study. Estimated AUC0-24 using 2 sampling times (2 – 3 and 6 – 8 hours after administration) showed a good predictive performance by the Bayesian approaches. Ten patients were included in the AUC0-24 equivalence study and the mean AUC0-24 ratio (VGCV/GCV) was 1.04. In this study, a higher inter-individual variability in AUC0-24 was observed after VGCV administration. In efficacy evaluation, a slower clearance of pp65 antigenemia was observed in patients with AUC0-24 of less than 40. Incidences of renal and hematological toxicity tend to be higher in patients with AUC0-24 more than 60, although not significant differences were noted between AUC0-24 groups.<br/> 【Conclusions】In this study, the systemic exposure of GCV following VGCV and GCV administration was equivalent. Lower exposure may cause prolongation of the dosing period, and long-term administration threatens patients with renal and hematological toxicity.</p>
Journal
-
- Japanese Journal of Transplantation
-
Japanese Journal of Transplantation 52 (4-5), 366-373, 2017
The Japan Society for Transplantation
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282680486953472
-
- NII Article ID
- 130006219173
-
- ISSN
- 21880034
- 05787947
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed